Last reviewed · How we verify
amlodipine and olmesartan — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
amlodipine and olmesartan (amlodipine and olmesartan) — InVasc Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| amlodipine and olmesartan TARGET | amlodipine and olmesartan | InVasc Therapeutics, Inc. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- amlodipine and olmesartan CI watch — RSS
- amlodipine and olmesartan CI watch — Atom
- amlodipine and olmesartan CI watch — JSON
- amlodipine and olmesartan alone — RSS
Cite this brief
Drug Landscape (2026). amlodipine and olmesartan — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-and-olmesartan. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab